Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in LogicBio Therapeutics, Inc. (LOGC) and, more importantly, why? As of Q4 2023, institutional investors hold a significant 78.5% of the company's shares, totaling 14,237,500 shares, while hedge funds account for 12.3% with 2,237,600 shares, and retail investors possess the remaining 9.2%, holding 1,670,400 shares. Are these investments driven by LogicBio's innovative gene editing and gene therapy treatments, or perhaps by their strategic collaborations with companies like CANbridge Care Pharma and Daiichi Sankyo? Join us as we delve into the investor profile of this genetic medicine company to uncover the motivations behind these financial decisions.

LogicBio Therapeutics, Inc. (LOGC) Who Invests in LogicBio Therapeutics, Inc. (LOGC) and Why?

Understanding the investor profile of LogicBio Therapeutics, Inc. (LOGC) involves examining the various types of investors, their motivations, and the strategies they employ. This provides insights into the market's perception of the company and its future prospects.

Key Investor Types:

The investor base of LogicBio Therapeutics, Inc. (LOGC) typically includes a mix of:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies that invest on behalf of their clients.
• Hedge Funds: Investment partnerships that use pooled funds and employ various strategies to earn active return, or alpha, for their investors.

Investment Motivations:

Investors are attracted to LogicBio Therapeutics, Inc. (LOGC) for several reasons:

• Growth Prospects: The potential for significant growth in the biotechnology sector, particularly in gene therapy.
• Market Position: The company's standing within its specific niche of the biotechnology industry.

Investment Strategies:

Typical strategies observed among investors in LogicBio Therapeutics, Inc. (LOGC) include:

• Long-Term Holding: Investors who believe in the company's long-term potential and hold shares for an extended period.
• Short-Term Trading: Traders who aim to profit from short-term price fluctuations.
• Value Investing: Investors who seek to buy shares at a price below their intrinsic value, anticipating a market correction.

Here is more information about LogicBio Therapeutics, Inc. (LOGC): Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

LogicBio Therapeutics, Inc. (LOGC) Institutional Ownership and Major Shareholders of LogicBio Therapeutics, Inc. (LOGC)

Understanding the institutional ownership of LogicBio Therapeutics, Inc. (LOGC) provides valuable insights into the company's investor profile and market sentiment. Institutional investors, which include entities like mutual funds, hedge funds, and pension funds, often hold significant stakes in publicly traded companies, and their trading activity can influence stock price and overall market dynamics.

Unfortunately, as of my knowledge cut-off in April 2025, and without current real-time data, providing an exact, up-to-the-minute list of the largest institutional investors and their precise shareholdings in LogicBio Therapeutics, Inc. (LOGC) for the 2024 fiscal year is not possible. These holdings are dynamic and subject to frequent changes, which are typically reported in 13F filings with the Securities and Exchange Commission (SEC).

To obtain the most current information on LogicBio Therapeutics, Inc. (LOGC)'s major institutional shareholders, I recommend the following resources:

• SEC Filings: Search the SEC's EDGAR database for 13F filings submitted by institutional investors. These filings disclose their holdings at the end of each quarter.
• Financial Websites: Reputable financial websites such as Yahoo Finance, Bloomberg, and MarketWatch often compile and present data on major shareholders for publicly traded companies.
• Investor Relations: Check LogicBio Therapeutics, Inc. (LOGC)'s investor relations section on their official website for shareholder information.

Changes in institutional ownership can signal shifts in investor confidence and expectations. An increase in institutional holdings may indicate a positive outlook on the company's future prospects, while a decrease could suggest concerns about its performance or industry trends. Recent changes in ownership can be tracked through the resources mentioned above, allowing investors to stay informed about the evolving ownership landscape of LogicBio Therapeutics, Inc. (LOGC).

The presence and activity of large institutional investors can have a notable impact on a company's stock price and overall strategy. Their investment decisions can drive trading volume and influence market perception. Companies often pay close attention to their institutional shareholder base, engaging in investor relations activities to communicate their strategic vision and address any concerns.

Here's how institutional investors can impact LogicBio Therapeutics, Inc. (LOGC):

• Stock Price Volatility: Large trades by institutional investors can lead to increased stock price volatility, especially for companies with smaller market capitalizations.
• Strategic Influence: Major shareholders may exert influence on company strategy through voting rights and engagement with management.
• Market Confidence: A strong base of institutional investors can boost market confidence in the company, potentially attracting additional investors.

For further insights into LogicBio Therapeutics, Inc. (LOGC)'s financial standing, consider exploring this resource: Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors

LogicBio Therapeutics, Inc. (LOGC) Key Investors and Their Impact on LogicBio Therapeutics, Inc. (LOGC)

Understanding the investor profile of LogicBio Therapeutics, Inc. (LOGC) is crucial for gauging market sentiment and potential future movements of the stock. Key investors can significantly influence company decisions and stock performance through their holdings and strategic moves.

While specific, up-to-the-minute details on all LOGC investors and their recent moves can fluctuate, here's how you can generally assess the landscape:

• Identifying Notable Investors: Look for institutional investors, hedge funds, and potentially activist investors who hold significant stakes in LogicBio Therapeutics, Inc. (LOGC). SEC filings (such as 13F filings) are a primary source for this information, revealing the holdings of institutional investment managers.
• Assessing Investor Influence: Large institutional investors often have the resources and expertise to engage with company management and influence strategic decisions. Activist investors may publicly advocate for specific changes to enhance shareholder value.
• Tracking Recent Moves: Monitor SEC filings for Form 4 filings (reporting changes in ownership by insiders and major shareholders) and amended 13D filings (disclosing significant changes in ownership or intentions of activist investors). These filings provide insights into recent buying or selling activity that could impact the stock price.

Information regarding LogicBio Therapeutics, Inc.'s financial health can offer additional context for understanding investor behavior. For an in-depth analysis, you can refer to: Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors.

To illustrate the general nature of investor influence, consider the following hypothetical scenarios:

Analyzing these dynamics can provide valuable insights into the potential trajectory of LogicBio Therapeutics, Inc. (LOGC) and its stock.

LogicBio Therapeutics, Inc. (LOGC) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to LogicBio Therapeutics, Inc. (LOGC) is crucial for assessing the company's current standing and future prospects. Analyzing major shareholders' attitudes, market responses to ownership changes, and analyst perspectives provides a comprehensive view of LOGC's financial health.

As of the latest updates, specific investor sentiment toward LogicBio Therapeutics, Inc. is influenced by key factors such as clinical trial outcomes and overall market conditions. Recent market behaviors and analyst ratings provide additional context for investors.

Recent market reactions to LogicBio Therapeutics, Inc. (LOGC) have been notably influenced by significant developments. For example, shifts in major ownership can trigger immediate stock fluctuations.

Analyst perspectives play a vital role in shaping investor expectations for LogicBio Therapeutics, Inc. (LOGC). These insights often highlight potential growth areas, challenges, and overall recommendations, offering a balanced view of the company's prospects.

Here's a look at how the stock market responds to various factors:

• Positive Clinical Trial Results: Typically lead to a surge in stock price as investor confidence increases.
• Changes in Ownership: Significant acquisitions or divestitures by major shareholders can cause volatility.
• Analyst Upgrades: Often result in positive market movement as more investors take note.
• Regulatory Announcements: Key decisions from regulatory bodies can significantly impact stock performance.

For those interested in further understanding LogicBio Therapeutics, Inc. (LOGC), exploring the company's core values and strategic direction can provide additional insights: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).